Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on therapies for rare cardiopulmonary disease, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). News about Liquidia often centers on its treprostinil‑based portfolio, including YUTREPIA™ (treprostinil) inhalation powder, the investigational L606 treprostinil liposome inhalation suspension, and its role in promoting generic Treprostinil Injection in the United States.
On this page, readers can follow company announcements related to YUTREPIA’s commercial launch, prescription trends and patient starts, as well as updates from ongoing clinical programs such as the ASCENT study in PH‑ILD. Liquidia regularly reports interim clinical data, including safety and exploratory efficacy findings, and provides context on how these results may inform treatment of PAH and PH‑ILD.
Investors and observers will also find coverage of quarterly financial results, revenue contributions from YUTREPIA and Treprostinil Injection, and details of corporate developments disclosed in press releases and SEC filings. These include financing arrangements, manufacturing expansion in Morrisville, North Carolina, and licensing agreements such as the exclusive U.S. license with Vectura for a nebulizer device used with L606.
In addition, Liquidia frequently participates in medical and investor conferences, R&D days and scientific meetings, where it presents new data on YUTREPIA and L606 and discusses its strategy in pulmonary hypertension. This news feed helps track how Liquidia advances its PRINT®‑enabled inhaled therapies, navigates litigation and regulatory milestones, and communicates with the medical and investment communities over time.
Liquidia Corporation (NASDAQ: LQDA) has announced that CFO Michael Kaseta will present a business overview during a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference. The session is scheduled for April 18, 2023, at 11:00 a.m. Eastern Standard Time.
Interested participants can access the live webcast on Liquidia's website, and an archived version will be available for 30 days post-event. Liquidia focuses on developing treatments for pulmonary hypertension and uses its proprietary PRINT® Technology. The company’s investigational product, YUTREPIA™, is aimed at treating pulmonary arterial hypertension.
Liquidia Corporation (NASDAQ: LQDA) announced a new, non-exclusive license agreement with GSK, replacing a prior collaboration from 2012. This agreement allows Liquidia to leverage its PRINT® technology for developing inhaled formulations, excluding certain GSK proprietary molecules. GSK retains a non-exclusive, royalty-free right for pre-clinical research. CEO Roger Jeffs highlighted benefits from restructuring the relationship to enhance product development opportunities. The earlier agreement had granted GSK an exclusive license in inhaled therapeutics, but the new terms require GSK to seek an expanded license for clinical or commercial use.
Liquidia Corporation (NASDAQ: LQDA) reported a net loss of $41 million for the full year ending December 31, 2022, with a revenue increase to $15.9 million from $12.9 million in 2021. The decrease in profit-sharing from its agreement with Sandoz, which fell from 80% to 50%, was countered by an increase in units sold. The company clarified its path to launching YUTREPIA, anticipating legal resolution by mid-2024, and has strengthened its financial position through various financing activities, including a $100 million revenue interest deal. The company's cash reserves increased to $93.3 million.
Liquidia Corporation (NASDAQ: LQDA) will announce its full-year 2022 financial results on March 16, 2023. A live webcast is scheduled for 8:30 a.m. Eastern Time, where the company will discuss its financial outcomes and provide a corporate update.
Liquidia is a biopharmaceutical firm focusing on pulmonary hypertension treatments, utilizing its PRINT® Technology. Its YUTREPIA™ inhalation powder has received tentative FDA approval for pulmonary arterial hypertension (PAH), indicating progress in its product development.
Liquidia Corporation (NASDAQ: LQDA) announced that the PTAB has upheld its decision declaring the ‘793 patent unpatentable, rejecting UTHR's rehearing request. The PTAB clarified that prior art cited by Liquidia was publicly distributed before the filing of the initial patent application. Liquidia anticipates a legal resolution regarding this patent by late 2023 or early 2024. UTHR is expected to appeal the PTAB's decision. If affirmed on appeal, the cancellation of the ‘793 patent will negate UTHR's infringement claims against Liquidia.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options for 10,000 shares to newly hired non-executive employees under its Inducement Plan. Each option, intended as part of the employment compensation, is exercisable at $6.39 per share, the closing price on the grant date of February 1, 2023. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. The Inducement Plan specifically allows for non-statutory stock options for individuals who are new hires or returning after a period of non-employment.
Liquidia Corporation (NASDAQ: LQDA) announced a Revenue Interest Financing Agreement with HealthCare Royalty (HCRx), securing up to $100 million to support the launch of YUTREPIA™ (treprostinil) inhalation powder and other business activities. Liquidia will receive an initial $32.5 million, with additional tranches contingent on conditions like patent litigation outcomes. The agreement is intended to extend Liquidia's cash runway through at least 2024, providing non-dilutive capital while maintaining financial flexibility.
Liquidia Corporation (NASDAQ: LQDA) announced a collaboration with Sandoz and Mainbridge Health Partners to develop a new subcutaneous infusion pump for Treprostinil Injection, a generic version of Remodulin. The Pump Agreement includes equal sharing of development costs and aims for FDA submission in 2023. Additionally, Liquidia and Sandoz extended their promotion agreement for Treprostinil Injection through 2032. This partnership emphasizes Liquidia's commitment to enhance treatment options for pulmonary arterial hypertension (PAH) patients.
Liquidia Corporation (NASDAQ: LQDA) reported its Q3 2022 financial results, maintaining revenue at $3.2 million year-over-year. The company is preparing to launch YUTREPIA™ for PAH and PH-ILD following legal victories against United Therapeutics. Liquidia's cash increased to $98.3 million, up from $57.5 million in December 2021. However, the net loss widened to $9.1 million compared to $7.3 million in Q3 2021, attributed to rising administrative expenses.
Anavasi Diagnostics, a medical technology firm, has elected three new board members: Bryan Crane, PhD, from Illumina, Arthur Kirsch from Liquidia Corp, and David Vied from Cyanotech Corporation. This expansion aims to leverage their extensive industry experience to enhance Anavasi's growth as it progresses through clinical trials and product development. Nelson Patterson, CEO, expressed optimism about the fresh perspectives these members will bring. Anavasi has secured $6 million in seed funding and is currently in a $20 million Series A fundraising round.